Previous 10 | Next 10 |
home / stock / soltf / soltf news
Tokyo, Japan and Cambridge, UK, 20 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on the Company’s scientific and early development strategy in su...
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditions NBI-1117570 is the second compound to advance into clinical development from a portfolio of selec...
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan , London and Cambridge , UK, 10 August 20 2 3 – Sosei Group Corporation (...
Tokyo, Japan and Cambridge , UK, 4 August 20 2 3 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023. The ...
Tokyo, Japan and Cambridge , UK, 20 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today’s announcement; “Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business i...
T ransaction adds complementary late-stage clinical development capability with profitable and fast-growing commercial operations in Japan Lean , go-to-market commercial model , well positioned to scale rapidly to...
Tokyo, Japan and Cambri dge , U K, 1 1 J uly 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2023 on Friday, 4 August 2023. ...
HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated with existing antipsychotic drugs Tokyo, Japan an...
Tokyo, Japan and Cambridge , UK, 27 June 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) notes the decision by its partner Pfizer to prioritize the development of clinical-stage GLP-1 receptor agonist candidate danuglipron for the treatment of diab...
2023-05-12 08:30:19 ET Sosei Group press release ( OTCPK:SOLTF ): Q1 GAAP EPS of -¥17.11. Revenue of ¥943M (-15.8% Y/Y). Outlook: At present, the Group has a strong cash runway into 2025 to fund its R&D activities. Our cost estimates and key initiati...
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on Friday, 9 August 2024. The Company will host a live webinar presentation with C...
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million...
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance (ESG) Report for the year ended 31 December 2023. The Annu...